Furthermore, in specific high-risk scenarios—such as patients with unexplained syncope, those with negative short-term electrocardiographic evaluations but high clinical suspicion of arrhythmia, individuals with Mayo Clinic stage III or higher disease, and patients who, despite achieving hematologic remission, exhibit fluctuating BNP levels or new-onset arrhythmic symptoms—the ICM has emerged as a pivotal “bridge” tool for long-term outpatient monitoring. This evidence concerns the gene NPPB and Arrhythmia.